Orchid Pharma Share Price
Sector: Biotechnology & Drugs
688.75 +26.45 (3.99%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
672.20
Today’s High
695.40
52 Week Low
603.80
52 Week High
1998
691.00 +30.85 (4.67%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
673
Today’s High
693.15
52 Week Low
603.80
52 Week High
1997.40
Key Metrics
- Market Cap (In Cr) 3493.28
- Beta 3.1
- Div. Yield (%) 0
- P/B 2.64
- TTM P/E 39.48
- Peg Ratio -
- Sector P/E 28.32
- D/E 0
- Open Price 695.4
- Prev Close 662.3
Orchid Pharma Analysis
Price Analysis
-
1 Week-10.94%
-
3 Months-28.34%
-
6 Month-61.74%
-
YTD-63.47%
-
1 Year-34.16%
Risk Meter
- 60% Low risk
- 60% Moderate risk
- 60% Balanced Risk
- 60% High risk
- 60% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 2
- 2
- 2
- 2
- Buy
- 1
- 1
- 1
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 3
- 3
- 3
- 3
Orchid Pharma News
Q4 results today: LIC, Info Edge, Minda Corp, Supriya Lifesciences, Bosch, more
2 min read . 27 May 2025Q4 results today: GIC, Aurobindo Pharma, Sumitomo Chemical, Nazara Tech, more
1 min read . 26 May 2025Stocks to Watch: Tata Tech, IREDA, Bharat Forge, Waaree Energies, and more
2 min read . 20 Feb 2025Stocks to watch: Vodafone Idea, IRCTC, JSW Steel, HUDCO, Orchid Pharma
8 min read . 13 Aug 2024Orchid Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 921.93
- Selling/ General/ Admin Expenses Total
- 86.36
- Depreciation/ Amortization
- 34.55
- Other Operating Expenses Total
- 174.17
- Total Operating Expense
- 839.3
- Operating Income
- 82.63
- Net Income Before Taxes
- 95.56
- Net Income
- 99.66
- Diluted Normalized EPS
- 19.65
- Period
- 2025
- Total Assets
- 1687.91
- Total Liabilities
- 420.63
- Total Equity
- 1267.29
- Tangible Book Valueper Share Common Eq
- 246.51
- Period
- 2025
- Cashfrom Operating Activities
- 19.22
- Cashfrom Investing Activities
- -26.93
- Cashfrom Financing Activities
- 25.22
- Net Changein Cash
- 17.51
- Period
- 2024
- Total Revenue
- 819.37
- Selling/ General/ Admin Expenses Total
- 84.94
- Depreciation/ Amortization
- 33.24
- Other Operating Expenses Total
- 55.16
- Total Operating Expense
- 741.74
- Operating Income
- 77.63
- Net Income Before Taxes
- 91.95
- Net Income
- 92.17
- Diluted Normalized EPS
- 19.08
- Period
- 2024
- Total Assets
- 1553.87
- Total Liabilities
- 384.41
- Total Equity
- 1169.47
- Tangible Book Valueper Share Common Eq
- 227.64
- Period
- 2024
- Cashfrom Operating Activities
- 125.99
- Cashfrom Investing Activities
- -312.03
- Cashfrom Financing Activities
- 167.04
- Net Changein Cash
- -19
- Period
- 2023
- Total Revenue
- 665.9
- Selling/ General/ Admin Expenses Total
- 117.32
- Depreciation/ Amortization
- 54.79
- Total Operating Expense
- 597.7
- Operating Income
- 68.2
- Net Income Before Taxes
- 55.25
- Net Income
- 46.32
- Diluted Normalized EPS
- 3.21
- Period
- 2023
- Total Assets
- 1225.21
- Total Liabilities
- 536.56
- Total Equity
- 688.65
- Tangible Book Valueper Share Common Eq
- 168.62
- Period
- 2023
- Cashfrom Operating Activities
- 18.34
- Cashfrom Investing Activities
- -31.21
- Cashfrom Financing Activities
- 31.17
- Net Changein Cash
- 18.29
- Period
- 2022
- Total Revenue
- 559.56
- Selling/ General/ Admin Expenses Total
- 63.28
- Depreciation/ Amortization
- 87.02
- Other Operating Expenses Total
- 129.59
- Total Operating Expense
- 593.45
- Operating Income
- -33.89
- Net Income Before Taxes
- -56.9
- Net Income
- -1.95
- Diluted Normalized EPS
- -14.8
- Period
- 2022
- Total Assets
- 1110.56
- Total Liabilities
- 463.18
- Total Equity
- 647.38
- Tangible Book Valueper Share Common Eq
- 158.53
- Period
- 2022
- Cashfrom Operating Activities
- 92.47
- Cashfrom Investing Activities
- 112.94
- Cashfrom Financing Activities
- -216.8
- Net Changein Cash
- -11.39
- Period
- 2021
- Total Revenue
- 450.06
- Selling/ General/ Admin Expenses Total
- 67.11
- Depreciation/ Amortization
- 108.92
- Other Operating Expenses Total
- 104.67
- Total Operating Expense
- 509.2
- Operating Income
- -59.14
- Net Income Before Taxes
- -95.25
- Net Income
- -116.53
- Diluted Normalized EPS
- -23.34
- Period
- 2021
- Total Assets
- 1237.25
- Total Liabilities
- 584.34
- Total Equity
- 652.91
- Tangible Book Valueper Share Common Eq
- 159.87
- Period
- 2021
- Cashfrom Operating Activities
- 23.59
- Cashfrom Investing Activities
- 67.21
- Cashfrom Financing Activities
- -164.99
- Net Changein Cash
- -74.2
- Period
- 2020
- Total Revenue
- 483.8
- Selling/ General/ Admin Expenses Total
- 74.86
- Depreciation/ Amortization
- 117.93
- Other Operating Expenses Total
- 177.46
- Total Operating Expense
- 573.61
- Operating Income
- -89.81
- Net Income Before Taxes
- -69.69
- Net Income
- -131.07
- Diluted Normalized EPS
- -17.1
- Period
- 2020
- Total Assets
- 1459.91
- Total Liabilities
- 693.92
- Total Equity
- 765.98
- Tangible Book Valueper Share Common Eq
- 181.6
- Period
- 2020
- Cashfrom Operating Activities
- 80.8
- Cashfrom Investing Activities
- 167.11
- Cashfrom Financing Activities
- -250.33
- Net Changein Cash
- -2.42
- Period
- 2019
- Total Revenue
- 599.98
- Selling/ General/ Admin Expenses Total
- 82.28
- Depreciation/ Amortization
- 129.94
- Other Operating Expenses Total
- 246.21
- Total Operating Expense
- 547.2
- Operating Income
- 52.78
- Net Income Before Taxes
- 69.41
- Net Income
- 69.41
- Diluted Normalized EPS
- -32.22
- Period
- 2019
- Total Assets
- 3077.04
- Total Liabilities
- 3781.07
- Total Equity
- -704.04
- Tangible Book Valueper Share Common Eq
- -20433.47
- Period
- 2019
- Cashfrom Operating Activities
- 12.02
- Cashfrom Investing Activities
- 45.47
- Cashfrom Financing Activities
- -0.3
- Net Changein Cash
- 57.2
- Period
- 2025-03-31
- Total Revenue
- 237.48
- Selling/ General/ Admin Expenses Total
- 22.24
- Depreciation/ Amortization
- 8.87
- Other Operating Expenses Total
- 49.24
- Total Operating Expense
- 218.37
- Operating Income
- 19.11
- Net Income Before Taxes
- 19.09
- Net Income
- 22.29
- Diluted Normalized EPS
- 4.4
- Period
- 2025-03-31
- Total Assets
- 1687.91
- Total Liabilities
- 420.63
- Total Equity
- 1267.29
- Tangible Book Valueper Share Common Eq
- 246.51
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 19.22
- Cashfrom Investing Activities
- -26.93
- Cashfrom Financing Activities
- 25.22
- Net Changein Cash
- 17.51
- Period
- 2024-12-31
- Total Revenue
- 217.34
- Selling/ General/ Admin Expenses Total
- 22.06
- Depreciation/ Amortization
- 8.61
- Other Operating Expenses Total
- 44.13
- Total Operating Expense
- 199.58
- Operating Income
- 17.76
- Net Income Before Taxes
- 22.45
- Net Income
- 20.78
- Diluted Normalized EPS
- 4.1
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 222.7
- Selling/ General/ Admin Expenses Total
- 20.06
- Depreciation/ Amortization
- 8.63
- Other Operating Expenses Total
- 41.14
- Total Operating Expense
- 200.99
- Operating Income
- 21.71
- Net Income Before Taxes
- 25.9
- Net Income
- 27.24
- Diluted Normalized EPS
- 5.37
- Period
- 2024-09-30
- Total Assets
- 1635.14
- Total Liabilities
- 410.9
- Total Equity
- 1224.24
- Tangible Book Valueper Share Common Eq
- 237.71
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -15.13
- Cashfrom Investing Activities
- -7.22
- Cashfrom Financing Activities
- 23.1
- Net Changein Cash
- 0.75
- Period
- 2024-06-30
- Total Revenue
- 244.41
- Selling/ General/ Admin Expenses Total
- 22
- Depreciation/ Amortization
- 8.44
- Other Operating Expenses Total
- 39.66
- Total Operating Expense
- 220.36
- Operating Income
- 24.05
- Net Income Before Taxes
- 28.12
- Net Income
- 29.35
- Diluted Normalized EPS
- 5.79
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 217.1
- Selling/ General/ Admin Expenses Total
- 16.72
- Depreciation/ Amortization
- 8.42
- Other Operating Expenses Total
- 42.43
- Total Operating Expense
- 195.69
- Operating Income
- 21.41
- Net Income Before Taxes
- 30.95
- Net Income
- 33.53
- Diluted Normalized EPS
- 6.62
- Period
- 2024-03-31
- Total Assets
- 1553.87
- Total Liabilities
- 384.41
- Total Equity
- 1169.47
- Tangible Book Valueper Share Common Eq
- 227.64
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 125.99
- Cashfrom Investing Activities
- -312.03
- Cashfrom Financing Activities
- 167.04
- Net Changein Cash
- -19
- Period
- 2023-12-31
- Total Revenue
- 220.59
- Selling/ General/ Admin Expenses Total
- 19.14
- Depreciation/ Amortization
- 9.27
- Other Operating Expenses Total
- 44.12
- Total Operating Expense
- 194.47
- Operating Income
- 26.12
- Net Income Before Taxes
- 30.19
- Net Income
- 29.43
- Diluted Normalized EPS
- 6.18
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Orchid Pharma Technical
Moving Average
SMA
- 5 Day676.11
- 10 Day709.05
- 20 Day749.62
- 50 Day774.22
- 100 Day1041.07
- 300 Day1265.16
Orchid Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 303.75
- -0.9
- -0.3
- 571.15
- 257.85
- 3381.76
- Panacea Biotec
- 479
- -25.2
- -5
- 581
- 112.7
- 2922.35
- Orchid Pharma
- 688.75
- 26.45
- 3.99
- 1998
- 603.8
- 3493.28
- Alembic
- 110.7
- -2.8
- -2.47
- 169
- 85.55
- 2837.19
- Gujarat Themis Biosyn
- 307.25
- -2.15
- -0.69
- 390
- 192.35
- 3347.96
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 26.05
- 2.4
- 11
- 22.95
- Panacea Biotec
- -
- 3.86
- 31.02
- 24.87
- Orchid Pharma
- 32
- 2.52
- 2.14
- 2.75
- Alembic
- 9.13
- 1.21
- 12.21
- 63.51
- Gujarat Themis Biosyn
- 68.53
- 13.47
- 35.83
- 35.51
Orchid Pharma Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-May-25
- Audited Results
- 12-Feb-25
- Quarterly Results
- 11-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 23-May-24
- Audited Results
- 08-Feb-24
- Quarterly Results
- 04-Nov-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 10-May-23
- Audited Results
- 09-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 26-Jun-25
- 27-May-25
- COM
- 21-Aug-24
- 24-Jul-24
- AGM
- 29-Nov-23
- 23-Oct-23
- POM
- 09-Aug-23
- 13-Jul-23
- AGM
- 15-Jul-22
- 22-Jun-22
- AGM
- 13-Aug-21
- 23-Jul-21
- AGM
- 29-Jun-21
- 07-Jun-21
- EGM



